A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

PI: Frank A. Vicini


  • Lung Cancer


Michigan: Maria Pappas (248) 553-0606


  • Lung cancer

Primary Objective:
To compare overall survival (OS) in patients with inoperable, early stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab.

Patient Population:
Patients must have histologically or cytologically proven Stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC) without radiographic evidence of nodal or distant involvement (N0M0). Patients may have T3 disease with the exclusion of multifocal tumors and pericardial involvement.